H ypertensive heart disease is a major risk factor for the development of coronary artery disease and sudden cardiac death.1-5 Recent interest has focused on the presence of potentially malignant ventricular arrhythmias in patients with systemic hypertensive disease because sudden death is caused by ventricular fibrillation or rapid tachycardia in almost all monitored cases. [6] [7] [8] [9] In the presence of left ventricular (LV) hypertrophy, ventricular arrhythmias (VA) are common in treated or temporarily untreated patients.267 Recently, James et a19 described a 26% prevalence of repetitive arrhythmias in untreated hypertensives; in that study, hypokalemia instead of LV hypertrophy was predictive for the presence of VA. This finding had also been discussed in the Multiple Risk Factor Intervention Trial (MRFIT) study10 and enhanced the debate on (drug-induced) hypokalemia as an important arrhythmogenic cofactor in hypertensive patients.1112 Data on prevalence, spontaneous variability, and prognostic relevance of VA in untreated normokalemic hypertensives are missing.
An association between hypertensive disease and fatal arrhythmias has also been gathered from victims of sudden cardiac death. In these patients, hypertensive disease'3 or necropsy findings of LV hypertrophy'4-17 were common. In addition, most of the studies also stressed the uncertain role of myocardial ischemia because of the high prevalence of ST segment depression in sudden cardiac death patients.5 '8"9 Clinically, the coincidence of coronary artery disease and hypertension is known to carry an increased risk of sudden death.5,20'21 However, myocardial ischemia as a potential link to sudden death18-20,22 frequently is not symptomatic in hypertensive patients.21'23 Recent use of stress testing in angiographically studied hypertensive patients indicates a high prevalence of asymptomatic myocardial ischemia.23 Similar data were obtained during daily activities by Holter recordings in another invasively controlled group of hypertensive patients and therefore raised the question of the prognostic impact and potential interaction with VA.23 26 
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In this prospective trial, 150 untreated and normokalemic hypertensive patients were studied to assess prevalence and interaction of VA and significant ST segment changes during 24-hour Holter recording. Spontaneous variability of both parameters was determined by restudying a randomized subgroup of 50 patients after 4 weeks of placebo. For prognostic assessment, all patients were reassessed after 3 years of follow-up.
Methods

Patient Selection
From 1984 through 1986, 150 consecutive patients referred for antihypertensive treatment were enrolled in this study. There were 56 women and 94 men with a mean age of 56±9 years (range, 35-79 years). Informed consent was obtained from all patients.
Patients were included in the study if systolic and diastolic pressures were >160 and >95 mm Hg, respectively, on 3 consecutive days (three measurements per day separated by 10-minute intervals) after 15 minutes resting in the horizontal position. Presence of different ECG criteria of LV hypertrophy documented on surface ECG on day 3 are summarized in Table 1 .27-31 Previous effective treatment of hypertension disqualified the patient from the study, and ineffective or untolerated treatment was stopped at least 1 week before assessment of the baseline criteria. Exclusion criteria included diagnostic evidence of symptomatic coronary artery disease or previous myocardial infarction based on history, surface ECG, and when suspected, exercise testing; hypertension caused by pheochromocytoma, aortic coarctation, etc.; patients with malignancies, pacemaker, atrial fibrillation, Wolff-Parkinson-White syndrome, valvular heart disease, heart failure (New York Heart Association class >11), second-and third-degree atrioventricular block; and patients with serum potassium levels less than 3.5 mmol/l. Concomitant medication with /-blocking agents, calcium channel-blocking agents, antiarrhythmic agents, potassium-depleting diuretics, and digitalis was not allowed.
Study Design
All patients (group A) underwent baseline examination including ECG, 24 -hour Holter monitoring (ana- lyzed time, >21 hours per patient), and repeated measurements of electrolyte plasma concentration. Blood pressure measurements were taken at the same time under standardized conditions (three consecutive measurements, separated by 10-minute intervals, after 15 minutes in horizontal position).
After baseline study, a subgroup of 50 of 150 patients (group B) were selected by randomization and treated with placebo twice a day for 4 weeks. In all other patients individual antihypertensive treatment was initiated, and the patients only were followed for prognostic reasons. All patients on placebo were restudied after 4 weeks of treatment, and at this time all baseline measurements were repeated.
Holter Recordings
All Holter recordings were performed using a twochannel bipolar recorder and analyzed semiautomatically after digitalization by a Cardiodata MK4 at the University of Freiburg. After careful preparation of the patient's skin, electrodes were positioned to obtain leads CM2 and CM5 and tested for artifact elimination by changing body position. Patients were carefully instructed to closely report daily activities in a detailed diary and to mark symptoms such as palpitations or angina pectoris by pressing a button on the event marker of the Holter recorder.
All Holter analyses were made without knowledge of clinical data and follow-up of the patient and were not considered for any clinical decision concerning the diagnostic and therapeutic regimen. Exceptions were made only when a sustained tachyarrhythmia was documented, which was the case in one patient with atrial fibrillation. During Holter analysis, calibrated tapes were replayed under visual control at 60 times normal speed. ST segment analysis was based on trend recordings of the difference between a reference point within the PQ segment and a point 80 msec after the J point within the ST segment. The relative ST segment deviation and heart rate were averaged over periods of 8 seconds and continuously plotted on a strip-chart recorder. ST segment depressions resulted in negative shifts of the ST segment trend. QRS complexes different from the sinus beat morphology were excluded from analysis. Horizontal or downsloping episodes with ST segment depression of .0.1 mV lasting for >1 minute were considered significant, and each was recorded at a paper speed of 25 mm/second. In patients with electrocardiographic evidence of LV hypertrophy, only an additional amount of ST segment depression of .0.15 mV lasting for >1 minute was considered. Episodes of ST segment depression were analyzed for duration, maximal ST segment depression, and heart rate at the beginning of ST segment depression.
Follow-up
After 36 months from entry in the study, an attempt was made to contact all patients to determine survival. A questionnaire evaluated the continuation of antihypertensive treatment and the occurrence of nonfatal myocardial infarction and fatal events such as myocardial infarction, death, and (SCD, defined as death within 1 hour after occurrence of symptoms). In patients with fatal events, further information was collected from the relatives to better classify the event. The diagnosis of coronary artery disease was only considered when documented by invasive measurements or scintigraphic imaging.
Statistical Analysis
Data are expressed as mean±+SD. (Figure 2) .
The correlation of VA, Sokolow-Lyon index, and ST segment depression is illustrated in Figure 4 . A positive relation (r=0.72) was present only in patients with ventricular pairs and salvos.
Follow-up of Patients With Hypertensive Disease
Data on 146 of 150 patients could be collected after 3 years of follow-up (Table 2 ). Eleven patients died: three 
Prevalence and Clinical Importance of Ventricular Arrhythmias in Hypertensive Patients
It is well known that systemic hypertension, with and without the presence of LV hypertrophy, carries an increased risk of sudden tachyarrhythmic death.1-5 The underlying mechanisms are still questioned, but ventricular pairs and salvos facilitated by arrhythmogenic cofactors (e.g., hypokalemia, myocardial ischemia) may play a dominant role. McLenachan et a16 reported an 8% prevalence of nonsustained ventricular tachycardia, increasing fourfold in the presence of LV hypertrophy. A study by Messerli et a12 also stressed the proarrhythmic effects of LV hypertrophy but included treated or only temporarily untreated patients and was characterized by a very low prevalence of arrhythmias in the control group. More recently, James et al,9 studying untreated hypertensives, observed a 12% prevalence of patients with >500 PVB per 24 hours; 40% of patients had ventricular pairs and salvos. LV hypertrophy was proarrhythmic only in the setting of hypokalemia, which limits conclusions from the former two studies in which diuretics and hypokalemia were observed in nearly half of the patients. The crucial role of hypokalemia was also stressed by the Oslo study32 and the MRFIT trial,10 with both providing evidence of more frequent events of SCD in the subgroups of patients with potassiumdepleting diuretic medication.
The present study was directed to a large group of untreated normokalemic hypertensives. Systemic hypertension was restrictively diagnosed by repetitive blood pressure measurements 1) 3) the reduced metabolic tolerance to ischemia51 lowering the fibrillation threshold; and 4) clinically, a close correlation between circadian blood pressure changes and the occurrence of ventricular arrhythmias.52 The latter three points stress the role of myocardial oxygen supply for the electrical instability of the hypertensive heart. Unfortunately, myocardial ischemia in hypertensive patients is frequently asymptomatic23 and, until recently, underestimated as to its incidence and prognostic relevance. 21'2353 Prevalence and Severity of Symptomatic uncertain whether the two risk factors stimulate each other or whether both VA and ST depression are covariate responses to an increased sympathetic drive. The prognostic impact of these observations becomes evident when we consider the well-known circadian rhythms of blood pressure and SCD.52,54 Blood pressure is highest and SCD most frequent during the early daytime, when hypertensive patients also suffer from an increase of ST segment depression and VA.
The fatal interaction of mostly asymptomatic myocardial ischemia and malignant VA, recently and controversially stressed in patients with known coronary artery disease,5556 may therefore provide a potential link to the increased risk of coronary artery disease and sudden death in hypertensive patients. 52 In this study, univariate analysis showed that frequently asymptomatic episodes of myocardial ischemia during daily activities, presence of LV hypertrophy, and presence of ventricular pairs and tachycardia were predictive for cardiac events during the follow-up. However, from a close interrelation of transient ST segmnent changes and repetitive VA, only transient ST segment changes and the presence of LV hypertrophy was shown to be of independent prognostic value. All three patients who died from SCD suffered from episodes of transient myocardial ischemia associated with the occurrence of VA. It would seem to be an important issue during the next years to early identify hypertensive patients who suffer from high risk of ischemic or arrhythmogenic complications. Presence of LV hypertrophy, transient episodes of myocardial ischemia, and the presence of ventricular pairs and salvos may help in early identification of these high-risk patients.
Clinical Implications
This study has several major implications for the diagnostic assessment and therapeutic regimen in patients with systemic hypertension. Single and repetitive VA are very common in untreated normokalemic hypertensives and show a characteristic day-and-night variation, similar to the circadian rhythm of SCD. However, with regard to the high spontaneous long-term variability, antiarrhythmic therapy in hypertensive patients should be used very restrictively. By contrast, from the interaction with VA and the independent prognostic value of transient episodes of frequently asymptomatic myocardial ischemia during daily activities, as well as from the worsened prognosis of hypertensive patients when coronary artery disease becomes manifest (myocardial infarction, etc.), ECG findings suggestive of transient myocardial ischemia should carefully be considered in this patient group. Hypertensive patients showing both risk factors or presenting with LV hypertrophy and evidence of myocardial ischemia during daily activities on 24-hour Holter recording appear to have the highest risk of fatal tachyarrhythmic events and should, therefore, be directed to consequent diagnostic and therapeutic interventions to cure or prevent myocardial ischemia instead of being treated with antiarrhythmics.
